Overview

Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

Comparative randomized, single dose, two-way crossover open-label study To investigate the bioequivalence of Montelukast from 5 mg chewable tablets(Sandoz, Egypt) and Singulair5 mg chewable tablets(Merck & Co. Inc. ), after a single oral dose administration of each to healthy adults under fasting conditions,

Phase:

Phase 1

Details

Lead Sponsor:

Genuine Research Center, Egypt

Collaborator:

Sandoz

Treatments:

Montelukast